ReviewFrontiers in molecular biosciences2026
Translational insights into miR-126 and miR-423: biomarkers and therapeutic targets in cancer, cardiovascular, metabolic and kidney diseases.
Review in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRNAs) are key post-transcriptional regulators that orchestrate complex gene regulatory networks controlling endothelial function, metabolic adaptation, inflammation, and tissue remodeling. Among them, miR-126-3p, miR-126-5p, and miR-423-5p have emerged as context-dependent modulators linking vascular biology with cardiometabolic and oncologic disorders. MiR-126, through its 3p and 5p strands, plays a central role in maintaining endothelial integrity and angiogenic homeostasis. By modulating phosphoinositide 3-kinase/protein kinase B (PI3K/AKT), mitogen-activated protein kinase (MAPK), and inflammatory signaling pathways, miR-126 regulates vascular repair, endothelial activation, and immune-vascular interactions. Reduced miR-126 expression is consistently associated with endothelial dysfunction, impaired angiogenic balance, and disease progression in diabetes, chronic kidney disease, and multiple cancers. In parallel, miR-423-5p regulates oxidative stress responses, transforming growth factor beta (TGF-β)-related pathways, and PI3K/AKT signaling in a context-dependent manner. Through modulation of redox balance, fibrotic remodeling, and cell survival pathways, miR-423-5p may exert either tumor-suppressive or pro-tumorigenic effects depending on cellular and microenvironmental conditions. In cardiometabolic and renal disorders, it contributes to microvascular dysfunction and inflammatory activation while also demonstrating translational potential as a circulating biomarker candidate. This review synthesizes shared and divergent signaling mechanisms governed by these miRNAs across disease states, emphasizing strand selection, target competition, and network-level cross-talk as determinants of context-specific outcomes. Understanding these multilayered regulatory interactions may support the development of network-oriented biomarker panels and precision RNA-based therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.